Fisher Asset Management LLC purchased a new position in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 41,334 shares of the company's stock, valued at approximately $547,000.
A number of other institutional investors have also modified their holdings of the business. Versant Capital Management Inc acquired a new position in Takeda Pharmaceutical in the 4th quarter valued at $26,000. Wilmington Savings Fund Society FSB acquired a new stake in shares of Takeda Pharmaceutical in the 3rd quarter worth approximately $40,000. BNP Paribas Financial Markets grew its holdings in Takeda Pharmaceutical by 416.0% in the third quarter. BNP Paribas Financial Markets now owns 3,220 shares of the company's stock valued at $46,000 after purchasing an additional 2,596 shares during the last quarter. Smithfield Trust Co increased its holdings in Takeda Pharmaceutical by 76.9% during the 3rd quarter. Smithfield Trust Co now owns 3,428 shares of the company's stock valued at $49,000 after acquiring an additional 1,490 shares in the last quarter. Finally, Erste Asset Management GmbH purchased a new position in shares of Takeda Pharmaceutical during the 3rd quarter worth approximately $52,000. 9.17% of the stock is owned by institutional investors and hedge funds.
Takeda Pharmaceutical Price Performance
Shares of NYSE:TAK traded down $0.14 on Monday, hitting $15.04. The company had a trading volume of 2,274,228 shares, compared to its average volume of 1,826,343. The company has a market cap of $47.84 billion, a PE ratio of 37.59, a PEG ratio of 0.24 and a beta of 0.46. The business has a 50 day moving average of $13.59 and a 200 day moving average of $13.90. Takeda Pharmaceutical Company Limited has a 52-week low of $12.57 and a 52-week high of $15.22. The company has a current ratio of 1.31, a quick ratio of 0.72 and a debt-to-equity ratio of 0.63.
Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last released its earnings results on Thursday, January 30th. The company reported $0.42 EPS for the quarter, topping the consensus estimate of $0.34 by $0.08. Takeda Pharmaceutical had a net margin of 4.53% and a return on equity of 9.39%. As a group, equities analysts anticipate that Takeda Pharmaceutical Company Limited will post 1.64 earnings per share for the current fiscal year.
Takeda Pharmaceutical Company Profile
(
Free Report)
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.
Further Reading
Before you consider Takeda Pharmaceutical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Takeda Pharmaceutical wasn't on the list.
While Takeda Pharmaceutical currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering when you'll finally be able to invest in SpaceX, Starlink, or X.AI? Enter your email address to learn when Elon Musk will let these companies finally IPO.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
